Group; no. or mean ± SD | |||||
---|---|---|---|---|---|
Variable | MPH | Placebo | Total | Statistic | p value |
3-month sample | |||||
Participants | 54 | 44 | 98 | ||
Sex, female:male | 29:25 | 22:22 | 51:47 | χ2 = 0.133 | 0.72 |
ADHD subtype, iADHD:cADHD:hADHD | 28:26:0 | 20:22:2 | 48:48:2 | χ2 = 2.674 | 0.26 |
Psychotherapy, GPT:CM | 24:30 | 20:24 | 44:54 | χ2 = 0.010 | 0.92 |
IQ | 113.89 ± 15.3 | 113.89 ± 15.4 | 113.81 ± 15.3 | t96 = 0.059 | 0.95 |
Age, yr | 34.02 ± 10.1 | 37.09 ± 9.3 | 35.40 ± 9.8 | t96 = −1.552 | 0.12 |
WURS-k | 39.63 ± 9.4 | 41.82 ± 8.0 | 40.61 ± 8.8 | t96 = −1.224 | 0.22 |
CAARS* | 104.43 ± 32.4 | 112.86 ± 35.6 | 108.21 ± 34.0 | t96 = −1.225 | 0.22 |
ICV, mm3* | 1386.37 ± 131.1 | 1384.76 ± 134.0 | 1385.64 ± 131.7 | t96 = 0.060 | 0.95 |
BDI* | 11.55 ± 6.9 | 12.72 ± 9.8 | 12.08 ± 8.3 | t75.089 = −0.664 | 0.51 |
Dose, mg/kg | 0.646 ± 0.27 | 0.826 ± 0.29 | 0.726 ± 0.29 | t91 = −3.069 | 0.003 |
1-year sample | |||||
Participants | 37 | 29 | 66 | ||
Sex, female:male | 17:20 | 14:15 | 31:35 | χ2 = 0.035 | 0.85 |
ADHD subtype, iADHD:cADHD:hADHD | 20:17:0 | 16:12:1 | 36:29:1 | χ2 = 1.357 | 0.51 |
Psychotherapy, GPT:CM | 18:19 | 16:13 | 34:32 | χ2 = 0.277 | 0.60 |
IQ | 114.22 ± 16.1 | 109.76 ± 14.6 | 112.26 ± 15.5 | t64 = 1.164 | 0.25 |
Age, yr | 33.97 ± 9.1 | 36.52 ± 9.9 | 35.09 ± 9.5 | t64 = −1.085 | 0.28 |
WURS-k | 38.24 ± 8.1 | 39.90 ± 7.1 | 38.97 ± 7.7 | t64 = −0.866 | 0.39 |
CAARS* | 104.90 ± 30.8 | 106.31 ± 30.9 | 105.52 ± 30.6 | t64 = −0.185 | 0.85 |
ICV, mm3* | 1394.29 ± 137.0 | 1373.58 ± 130.6 | 1385.19 ± 133.6 | t64 = 0.622 | 0.54 |
BDI* | 11.35 ± 8.13 | 13.62 ± 9.6 | 12.35 ± 8.1 | t64 = −1.134 | 0.26 |
Dose, mg/kg | 0.660 ± 0.24 | 0.833 ± 0.29 | 0.736 ± 0.27 | t64 = −2.667 | 0.010 |
ADHD = attention-deficit/hyperactivity disorder; BDI = Beck Depression Inventory; CAARS = Conner’s Adult ADHD Rating Scale; cADHD = combined subtype; CM = clinical management; GPT = group psychotherapy; hADHD = hyperactive-impulsive subtype, iADHD = inattentive subtype; ICV = intracranial volume; MPH = methylphenidate; WURS-k = Wender Utah Rating Scale.
↵* Measured at baseline.